Roth Capital analyst George Kelly lowered the firm’s price target on Gen Restaurant Group (GENK) to $3 from $5 and keeps a Buy rating on the shares. The firm is resetting estimates lower following the company’s weak Q3 report in mid-November. Conditions remain challenged due to competitive and industry-wide pressures, and Roth’s updated 2026 estimates now reflect fewer net openings as management slows new builds. Restaurant level profitability and cash-on-cash return remain solid, but until comparable sale ...

Core Viewpoint - BofA analyst Ken Hoexter raised the price target on Schneider National (SNDR) to $28 from $26 while maintaining a Neutral rating on the shares, indicating a cautious outlook despite a slight increase in the price target [1] Financial Estimates - The firm adjusted its Q4 EPS estimate for Schneider National down to 19 cents from 21 cents, which is below both the company's and Street targets [1] - For FY25 and FY26, the EPS estimates were lowered by 2% and 7% respectively, reflecting a more conservative outlook [1] Market Conditions - The analysis notes sluggishness in November before a projected rise in spot rates in December, suggesting a challenging market environment in the short term [1] - Despite the lowered EPS estimates, the price target was raised due to an improved outlook for rates leading into 2026 [1]

Group 1 - Piper Sandler analyst John Barnidge raised the price target on Lincoln National (LNC) to $48 from $42 while maintaining a Neutral rating on the shares [1] - The firm is generally above consensus across the board in the life insurance sector [1] - The gradual drop in rates has been more constructive for broader capital markets activity, likely providing a tailwind to fee and spread earnings in its coverage [1]

Group 1 - Piper Sandler raised the price target on Principal Financial (PFG) to $100 from $94, maintaining an Overweight rating on the shares [1] - The firm is generally above consensus across the board in the life insurance sector [1] - The gradual drop in rates has positively impacted broader capital markets activity, providing a tailwind to fee and spread earnings in its coverage [1]

Piper Sandler raised the firm’s price target on Prudential (PRU) to $120 from $110 and keeps a Neutral rating on the shares. The firm is generally above consensus across the board in lifecoland. The drop in rates has been more gradual than has otherwise been expected, which has been constructive for broader capital markets activity too. This likely causes some tailwind to fee and spread earnings in its coverage, Piper adds. Claim 70% Off TipRanks This Holiday Season Published first on TheFly – the ultima ...

Core Viewpoint - Jefferies has adjusted its price target for Paychex, Inc. to $110, indicating a potential downside from the current trading price of $112.28 [1][2][5] Financial Performance - During the Q2 2026 earnings call, key figures from Paychex discussed the company's financial performance and strategic direction, with participation from analysts at major financial institutions [3] - Paychex's market capitalization is approximately $40.44 billion, reflecting its significant presence in the industry [4][5] Stock Performance - The stock experienced a decrease of about 1.72% during the trading day, dropping by $1.96, with a trading range between $109.03 and $114.12 [2][5] - Today's trading volume reached 11,297,629 shares, indicating active investor interest in PAYX [4] Market Volatility - The stock's 52-week range shows a high of $161.24 and a low of $108, indicating considerable volatility in its price [4][5]

Group 1 - Morgan Stanley raised the price target on V2X (VVX) to $61 from $58 while maintaining an Underweight rating on the shares [1] - The firm observes encouraging signs of backlog growth heading into the new year [1] - Significant drivers of performance will include contract ramp-up and roll-offs, as well as alignment to market subverticals [1]

Summary of Key Points Core Viewpoint - BofA has lowered the price target for AbbVie (ABBV) to $233 from $248 while maintaining a Neutral rating on the shares, indicating a cautious outlook on the stock's performance moving forward [1]. Group 1: Valuation and Growth Outlook - The firm perceives "a relatively clean setup" for growth at the high end of the peer group, suggesting that AbbVie has potential for growth compared to its competitors [1]. - The valuation basis is being shifted to FY27 estimates, indicating a long-term perspective on the company's financial performance [1]. Group 2: Pipeline and Market Position - The premium multiple assigned to AbbVie is balanced by limited late-stage pipeline catalysts, which may restrict significant upside potential in the near term [1].

Group 1 - Analyst Jason Kolbert from D. Boral Capital raised the price target on Quince Therapeutics (QNCX) to $5 from $4, maintaining a Buy rating on the shares [1] - The increase in the price target follows the completion of the last patient visit in the pivotal Phase 3 NEAT clinical trial for encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia [1] - The firm attributes the target increase to the rolling of its valuation metrics out a year [1]

Group 1 - Cantor Fitzgerald raised the price target on Mirum Pharmaceuticals (MIRM) to $130 from $95, maintaining an Overweight rating on the shares [1] - Mirum's proposed acquisition of Bluejay Therapeutics is valued at $250 million in cash, $300 million in stock, and $200 million in tiered milestone payments, which is considered a "steal" by the analyst [1]